DroneShield Ltd (ASX: DRO) shares are getting a lot of attention on Monday.

In morning trade, the counter drone technology company’s shares were up over 5% to $2.94 at one stage.

At the time of writing, they have pulled back but remain up almost 1% to $2.80.

Why are DroneShield shares in focus today?

Investors have been buying the company’s shares today after it released an update on its governance review.

DroneShield launched its independent review into its continuous disclosure and securities trading policies and other areas last month after a series of controversies that sparked a sharp selloff.

According to the release, the review was overseen by independent directors Simone Haslinger and Richard Joffe, whereas Herbert Smith Freehills Kramer was engaged to undertake the review.

Following completion of the review last week, the DroneShield board has undertaken immediate action.

What action is being taken?

In response to its directors selling down their holdings last month, DroneShield’s board revealed that it will establish a mandatory minimum shareholding policy (MSP) for all directors and members of senior management.

Under the MSP, each director will be expected to hold ordinary shares in the company equivalent in value to their annual base fee within three years from the establishment of the MSP.

For the CEO, they will be expected to hold ordinary shares in the company equivalent in value to 200% of their annual salary within 12 months from the MSP’s establishment.

DroneShield will also update its securities trading policy and continuous disclosure policy to align them with market practice and expectations of an ASX 200 company. The market will be notified once these policies have been updated.

Another action being taken is the board initiating a search for a suitable candidate to be appointed as an additional independent non-executive director with ASX 200 experience.

Remuneration structure review

DroneShield also advised that its board is undertaking a review of the director and executive remuneration framework, supported by PayIQ Executive Pay.

The review will focus on aligning the company’s remuneration arrangements with the expectations for an ASX 200 share and the dynamic industry in which the company operates.

It is intended that an update on this review will be provided in the company’s next remuneration report, which will be published in February.

Process improvements

Finally, in response to the withdrawal of an announcement last month, DroneShield advised that it is continuing to enhance the verification processes.

In addition, following the conclusion of the ERP implementation in January, an appropriately qualified external adviser will undertake a broader review of the company’s financial reporting processes and internal controls.

The post Why is everyone talking about DroneShield shares today? appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• 3 ASX 200 stocks storming higher in this week’s sinking market
• 2026 will be the ‘Year of the Drone’: Buy DroneShield shares
• 5 things to watch on the ASX 200 on Thursday
• Why is the DroneShield share price crashing 13% on Wednesday?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended DroneShield. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Ten years ago, Apple (NASDAQ: AAPL) carried a market cap of $591 billion. At the time, it was the most valuable business in the world. What’s impressive is that even coming off a massive starting base, this company has continued to grow. It now sports a market cap of more than $4 trillion (as of Dec. 20).

This means that long-term shareholders have benefited. If you’d invested $1,000 in this consumer discretionary stock 10 years ago, here’s how much you’d have today. 

Apple has been crushing the market

A $1,000 starting sum to buy Apple shares in December 2015 would be worth $11,450 right now. This translates to a total return of 1,040%. That gain includes the dividend, which is a small payout today at $0.26 per quarter. However, the dividend has increased by 100% in the past 10 years.

The S&P 500‘s total return during the same time period of 305% comes up well short of Apple’s.

Financial results and valuation drive the stock

Between fiscal 2015 and fiscal 2025 (ended Sept. 27), Apple’s revenue soared 78%, as it sold more of its popular hardware devices and saw its services segment grow rapidly. Net income rose 110% over that time. But valuation expansion was the biggest tailwind for the stock.

Looking out at the next decade, Apple’s more muted growth prospects mean that investors shouldn’t expect past returns to repeat.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post If you’d invested $1,000 in Apple 10 years ago, here’s how much you’d have today appeared first on The Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

More reading

• How to invest your first $1,000 in the share market the smart way
• 3 ASX ETFs I’d buy right now to build wealth
• The ASX ETFs I’d buy for my kids or grandkids
• Screaming buy? This ASX ETF has returned 54% a year since 2022
• Billionaire Peter Thiel just sold Nvidia and Tesla for these other two “Magnificent Seven” stocks

Neil Patel has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Apple. The Motley Fool Australia has recommended Apple. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Lendlease Group (ASX: LLC) share price is in focus today after the company announced a ~$400 million sale of its interests in The Exchange TRX in Malaysia, and gave investors an update on its Capital Release Unit (CRU) for FY26.

What did Lendlease report?

• Binding agreement to sell a 40% interest in The Exchange TRX retail mall and full 60% interest in the adjacent office tower for ~$400 million
• Lendlease retains a 20% interest in the retail mall and 60% stakes in the adjoining hotel and residential land plots
• Targeting $2 billion in capital recycling from the CRU during FY26
• Net debt reduction target: 15% Group gearing by the end of FY26, excluding hybrid benefit
• CRU expected to post a loss in 1H FY26 due to transaction delays and higher holding costs

What else do investors need to know?

Lendlease’s $400 million sale to Malaysia’s Valiram Family Office forms part of a broader push to recycle capital and strengthen its balance sheet. The transaction—which is still subject to financing and third-party approvals—is expected to complete in the second half of FY26.

The company continues to pursue exclusive negotiations for the sale of its remaining share in Keyton, with further ~$1 billion in CRU asset sales in progress. However, delays in transaction timing mean anticipated cash inflows of ~$1 billion, initially expected in the first half, are now forecast for the second half of FY26.

On the back of these delays, Lendlease expects higher than previously forecast gearing in 1H FY26, reaching the mid- to high-30% range (excluding a 7% hybrid securities benefit to statutory gearing).

What did Lendlease management say?

Lendlease Group CEO Tony Lombardo said:

We are pleased to announce further progress on our capital recycling initiatives, with $400 million to be released from the high quality Exchange TRX retail mall and office assets.

We continue to be highly active on capital recycling, with more than $3 billion of transactions underway for the second half of the financial year. This includes $2 billion of announced or advanced stage capital recycling initiatives across our segments.

What’s next for Lendlease?

Lendlease says it remains focused on its ~$2 billion capital recycling target from the CRU in FY26, including asset disposals already announced and ongoing sales processes. The group has also flagged significant planned capital expenditure on growth projects like One Circular Quay and Victoria Harbour, which are expected to deliver more than $1 billion in proceeds upon settlement in FY27.

No specific earnings guidance has been provided for the CRU segment for FY26. Management is balancing speed of execution with achieving value for shareholders as it completes these transactions.

Lendlease share price snapshot

Over the past 12 months, Lendlease shares have declined 20%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post Lendlease unveils $400m TRX sale and FY26 capital recycling update appeared first on The Motley Fool Australia.

More reading

• Reece announces $85 million on-market buyback target
• Regis Healthcare CEO resignation: Leadership transition update
• Aurizon lodges new 10-year network access undertaking with QCA
• Stockland announces estimated 1H26 distribution
• Champion Iron launches $289m Rana Gruber takeover: what shareholders need to know

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Reece Ltd (ASX: REH) share price is in focus today after the company boosted its on-market share buyback target by $50 million, bringing the total to $85 million. The buyback reflects a disciplined approach to capital management and ongoing focus on delivering shareholder value.

What did Reece report?

• Increased its on-market share buyback target from $35 million to $85 million
• The buyback will be funded from existing cash reserves and debt facilities
• The program commenced on 12 December 2025 and may run up to 12 months
• Actual purchase amount and timing will depend on share price and market conditions
• No change to Reece’s balance sheet strength or conservative leverage ratio

What else do investors need to know?

Reece Group’s decision to expand the buyback signals confidence in its financial position and outlook. The Board has emphasised that managing capital efficiently remains a top priority, supporting both future growth and shareholder returns.

The buyback is described as occurring in the ordinary course of ASX trading. Reece says the final number of shares repurchased and the timing will be adjusted as needed, based on ongoing market factors.

What did Reece management say?

Chairman and CEO Peter Wilson commented:

Further to the announcement of our on-market share buyback on 27 November 2025, the Board has approved an increase to the total target, now set at $85 million. This reflects our disciplined approach to capital management and ongoing commitment to delivering shareholder value. We continue to focus on maintaining a strong balance sheet with a conservative leverage ratio to fund future growth.

What’s next for Reece?

The company plans to continue its buyback program over the coming year, watching market movements and its own capital needs. Maintaining a strong balance sheet and conservative leverage will underpin its ongoing investment and growth strategy.

Shareholders can expect Reece to remain focused on prudent financial management as it navigates changing market conditions. Management has reaffirmed the company’s commitment to operational strength and long-term growth ambitions.

Reece share price snapshot

Over the past 12 months, Reece shares have declined 44%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 6% over the same period.

View Original Announcement

The post Reece announces $85 million on-market buyback target appeared first on The Motley Fool Australia.

More reading

• Lendlease unveils $400m TRX sale and FY26 capital recycling update
• Regis Healthcare CEO resignation: Leadership transition update
• Aurizon lodges new 10-year network access undertaking with QCA
• Stockland announces estimated 1H26 distribution
• Champion Iron launches $289m Rana Gruber takeover: what shareholders need to know

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

The All Ordinaries Index (ASX: XAO) is up 0.5% on Monday morning, with ASX All Ords gold stock Rox Resources Ltd (ASX: RXL) racing ahead of those gains.

Rox Resources shares closed up 7.1% on Friday, trading for 45.5 cents. At the time of writing, shares are changing hands for 46 cents apiece, up 1.1%.

This sees shares in the ASX All Ords gold stock up a whopping 130% over 12 months.

Here’s what’s happening today.

ASX All Ords gold stock invests in gold price ‘insurance’

The Rox Resources share price is pushing higher after the miner announced it has invested in put options to protect against any potential decline in gold prices.

The ASX All Ords gold stock bought the put options from an unnamed “leading Australian bank”. The miner paid an upfront premium of $9.7 million for the put options, which cover 40,400 ounces of gold.

The company said this will provide it with important cash flow protection during the first full year of production at its Youanmi gold mine, located in Western Australia, helping to de-risk the project’s ramp-up.

The put options will cover approximately half of the forecast FY 2028 gold production at Youanmi.

They have a strike price of $5,700 per ounce.

If you’re not familiar with put options, this means that Rox Resources has the right, but not the obligation, to sell ounces at the strike price at monthly maturities, which are split between the four quarters of FY 2028.

The ASX All Ords gold stock highlighted that it retains full exposure to rising gold prices, as it can simply let the options expire if the gold price is higher than the strike price at the time of maturity.

Rox added that the put option strike price is $500 per ounce above its November 2025 Definitive Feasibility Study (DFS) gold price assumption of $5,200 per ounce.

The gold spot price currently sits at US$4,339 per ounce ($6,552 per ounce in Aussie dollars).

What did Rox Resources management say?

Commenting on the put option investment that looks to be helping boost the ASX All Ords gold stock today, chief financial officer Greg Hoskins said:

For a modest outlay of under $10 million, the strategic purchase of gold put options provides valuable gold price protection and underwrites strong cash flow generation during the first full year of production at Youanmi.

Importantly, Rox maintains full exposure to rising gold prices, with its exposure capped at the upfront cost. We look forward to finalising the competitive project financing process in the new year and progressing towards a Final Investment Decision.

The post Up 130% in a year, ASX All Ords gold stock lifts off on ‘valuable gold price protection’ news appeared first on The Motley Fool Australia.

More reading

• Is it too late to buy surging ASX lithium shares like Mineral Resources and Liontown?
• Why is everyone talking about DroneShield shares today?
• If you’d invested $1,000 in Apple 10 years ago, here’s how much you’d have today
• Lendlease unveils $400m TRX sale and FY26 capital recycling update
• Reece announces $85 million on-market buyback target

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Regis Healthcare Ltd (ASX: REG) share price is in focus today after the company announced CEO and managing director Dr Linda Mellors will step down following six years at the helm.

What did Regis Healthcare report?

• Dr Linda Mellors has resigned as CEO and MD of Regis Healthcare after more than six years in the role.
• She will remain with the company during a six-month notice period to support a smooth transition.
• Regis has commenced an executive search to appoint a new CEO.
• Regis remains in a strong financial and operating position, according to the board.
• The company has recently navigated significant reforms, including the new Aged Care Act.

What else do investors need to know?

Dr Mellors’ departure comes after a period marked by sector reforms, the Royal Commission into Aged Care, and the COVID-19 pandemic. During her tenure, Regis invested heavily to enhance service quality and strengthen its executive team. The board has highlighted these achievements and reassured investors of Regis’ continued strong position.

The succession process is underway, with Dr Mellors set to remain active until a replacement is found. Regis’ board has underlined its commitment to strong governance and ongoing growth through this transition.

What did Regis Healthcare management say?

Regis chairman Graham Hodges said:

On behalf of the Board, I want to thank Linda for her outstanding leadership and commitment to Regis and the aged care sector more broadly. During her tenure, Linda has guided the company through a period of significant transformation and growth, including through the Royal Commission into Aged Care, the COVID pandemic and the more recent reforms associated with the new Aged Care Act. Her leadership of Regis has delivered significant growth in the business together with important investments in people, processes, and systems to maintain our focus on high quality care. Linda leaves the business in a strong financial and operating position and with a capable and experienced executive team. We wish her every success in the next chapter of her career.

What’s next for Regis Healthcare?

Regis will commence an executive search for its next CEO, aiming for a seamless leadership transition. The company has stated it remains focused on delivering quality care and driving operational improvements as the aged care sector continues to evolve.

With a strong financial footing and an experienced leadership team, Regis says it is well-placed to keep investing in service quality and adjusting to future industry reforms.

Regis Healthcare share price snapshot

Over the past 12 months, Regis Healthcare shares have increased 16%, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 5% over the same period.

View Original Announcement

The post Regis Healthcare CEO resignation: Leadership transition update appeared first on The Motley Fool Australia.

More reading

• Lendlease unveils $400m TRX sale and FY26 capital recycling update
• Reece announces $85 million on-market buyback target
• Aurizon lodges new 10-year network access undertaking with QCA
• Stockland announces estimated 1H26 distribution
• Champion Iron launches $289m Rana Gruber takeover: what shareholders need to know

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Telix Pharmaceuticals Ltd (ASX: TLX) shares are starting the week in a positive fashion.

In morning trade, the radiopharmaceuticals company’s shares are up 2% to $12.25.

Why are Telix shares charging higher?

Investors have been buying the company’s shares today following the release of a major portfolio update.

Telix has provided investors with progress updates across several of its key diagnostic imaging programs, including positive clinical data in China and regulatory developments in the United States.

This includes phase 3 trial results for Telix’s prostate cancer imaging agent, TLX591-CDx, marketed as Illuccix in approved jurisdictions.

According to the release, the company has received positive top-line data from its phase 3 registration study in Chinese patients with biochemical recurrence of prostate cancer.

The study met its primary endpoint, delivering a patient-level positive predictive value of 94.8% for tumour detection. Importantly, its performance remained strong even in patients with very low PSA levels, which is considered a key clinical challenge.

Management believes that these results support a near-term new drug application submission in China, which it has described as a “strategically important” market. Telix is running the program alongside its commercial partner, Grand Pharmaceutical Group, which already has an established presence in the region.

Commenting on the study, Telix’s chief medical officer, Dr. David N. Cade, said:

This is an outstanding result. The primary endpoint of the study was met decisively, with the positive predictive value significantly exceeding the performance threshold agreed with the Chinese regulator. Importantly, the high PPV was consistent even in patients with very low PSA values, and across differing metastatic locations, demonstrating broad clinical applicability. These compelling data will enable Telix and our partner Grand Pharma to submit a New Drug Application for Illuccix in China, a strategically important market.

Telix highlights that in China, there were more than 134,000 men diagnosed with prostate cancer in 2022, increasing by approximately 6% each year.

And in line with government policy supporting wider geographic access to nuclear medicine, the number of PET/CT cameras installed in China is expected to surpass 1,600 by the end of 2025, compared with just 133 in 2010.

Regulatory progress in the United States

Telix also updated the market on the regulatory pathway for two other diagnostic candidates in the United States.

For TLX101-CDx (Pixclara), a PET imaging agent for glioma, the company confirmed that it is finalising its resubmission to the US Food and Drug Administration (FDA) following a Complete Response Letter earlier this year. Management advised that it has had collaborative discussions with the FDA and expects to provide a further update once the resubmission has been accepted.

Meanwhile, the company reported constructive engagement with the FDA regarding TLX250-CDx (Zircaix), its kidney cancer imaging candidate. It notes that a recent Type A meeting aligned Telix and the regulator on addressing chemistry, manufacturing, and controls issues that were previously raised. An additional FDA meeting is scheduled for January to review plans relating to manufacturing comparability data.

Overall, it has been a tough year for Telix, but it does appear to be getting its ducks in a line now.

The post Telix shares storm higher on big US and China news appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• Telix Pharmaceuticals in focus with China trial success and FDA updates
• Bell Potter names the best ASX healthcare shares to buy in 2026
• Why is everyone talking about Telix shares this week?
• 5 ASX shares I’d buy with $10,000 this week

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Immutep Ltd (ASX: IMM) has reported positive results from a clinical trial of a drug it is developing in a bid to treat autoimmune diseases in a novel fashion.

The biotechnology company said in a statement to the ASX on Monday morning that the “single-ascending dose escalation” portion of the phase one clinical trial of its compound, IMP761, had completed the 2.5 and 7mg per kg dosing levels, “with continued positive safety and efficacy data”.

As the company said:

IMP761 was tolerated well with no treatment-related adverse reactions beyond mild intensity. Additionally, evidence of dose-dependent immunosuppressive effects with IMP761 was observed with significant, long-last inhibition of the three T-cell mediated intradermal reactions to a strong foreign antigen at day 2, 9 and 23.

Key milestone for the company

Immutep’s Chief Scientific Officer, Dr Frederic Triebel, said the results were encouraging.

He went on to say:

We are excited to see IMP761 having a long-term immunosuppressive effect after a single injection. A solid pharmacokinetic/pharmacodynamic relationship has now been established between 1 and 7mg per kg with eight participants per group to cover the variability of the responses. This novel immunotherapy’s significant level of immune suppression combined with its favourable safety provide proof of concept data in its potential to silence the dysregulated T cells at the epicentre of many autoimmune diseases. Encouragingly our clinical progress with IMP761 has corresponded with increased external interest in the program.

Various ailments in focus

Immutep said the LAG-3 “immune checkpoint” has been identified as a promising therapeutic target for many autoimmune diseases, including rheumatoid arthritis, type 1 diabetes, and multiple sclerosis.

It went on to say:

IMP761 is the first LAG-3 agonist antibody developed to potentially treat these large, increasingly prevalent disorders, each of which represent multi-billion dollar markets. By enhancing the ‘brake’ function of LAG-3 to silence dysregulated self-antigen-specific memory T cells, IMP761 is designed to target the cause of autoimmune diseases and restore balance to the immune system. LAG-3 expression on activated T cells demonstrates high specificity for disease sites, especially in regions characterised by chronic inflammation. This distinct characteristic of the LAG-3 immune checkpoint suggests IMP761 may enable a more targeted therapeutic approach with fewer adverse effects compared to other treatments.

Immutep said the clinical trial would continue, with further updates expected in the first half of calendar 2026, including a potential presentation of the trial data at a major medical conference.

The company’s shares were 0.7% lower at 39.3 cents on the news on Monday morning.

Immutep was valued at $582.1 million at the close of trade on Friday.

The post Clinical trial of potential diabetes and arthritis treatment delivers positive results appeared first on The Motley Fool Australia.

More reading

• Broker says this small cap ASX stock can rise ~90% following ‘impressive deal’
• Why Brightstar Resources, Immutep, Pilbara Minerals, and Race Oncology shares are roaring higher
• Guess which ASX 300 healthcare share is rocketing 28% on global expansion news

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Another way to gain exposure to the mining sector is by investing in companies that provide services such as engineering, construction, and site services to miners and explorers. Bell Potter believes there’s money to be made by investing in three of these firms.

The analyst team at Bell Potter has said in its end-of-year wrap-up to clients that iron ore and gold production is set to rise over the next three years, “benefiting services companies leveraged to mining volumes”.

They went on to say:

In exploration markets, the cycle has clearly demonstrated an inflection, with exploration facing companies reporting increased activity and demand for their services. Junior equity raisings have recently trended above the 2021 and 2011 peaks; as a leading indicator, we expect junior exploration activity to lift meaningfully over CY26.

The analyst team says while East Coast infrastructure looks “patchy” going forward, key sub-sectors such as energy generation, storage, transmission, and water utilities are looking good.

The rapidly expanding data centre sector would also provide tailwinds for companies in the infrastructure game.

So who do they like in the sector?

Develop Global Ltd (ASX: DVP)

This company is a bit different to a straight mining services company, given it is an underground mining contractor as well as the operator of two mining projects – the Woodlawn Zinc-Copper Mine in New South Wales and the Sulphur Springs Zinc-Copper Project in Western Australia.

The company also just last week announced it had won a $200 million contract at OceanaGold‘s Waihi North Project in the North Island of New Zealand.

Bell Potter said in its note to clients that the company is expected to ramp up to commercial production at Woodlawn in the March quarter of 2026, “representing a major re-rate catalyst”.

Bell Potter has a $5.20 price target on Develop Global shares, compared with the price of $4.36 currently.

IPD Group Ltd (ASX: IPG)

IPD, the Bell Potter team said, delivered better than expected first-half guidance at its recent annual general meeting, and was well-leveraged to the strong spend around data centres and infrastructure.

They said IPD had a “current strong order book and pipeline opportunities”, and strong free cash flow over the next two financial years “should support de-leveraging and balance sheet flexibility to target multiple accretive bolt-on acquisitions”.

Bell Potter has a $5 price target on IPD shares compared with $4.07 currently.

Duratec Ltd (ASX: DUR)

This company wins a high level of repeat business in the Western Australian engineering field, due to its reputation and quality of completed projects, Bell Potter said.

Its track record of growth is aided by bringing specialist contractors into the group, adding new customers and markets. The FY25 results saw growth in energy and emerging sectors, with revenue up by 77% to $82.5m and 175.5% to $60.6m respectively, nearly all delivered organically.

The company also has exposure to the defence sector, which should benefit from the AUKUS work to begin soon.

Bell Potter has a $1.90 price target on Duratec shares compared with $1.79 currently.

The post Bell Potter names three engineering companies to buy appeared first on The Motley Fool Australia.

More reading

• Top broker just raised its price target on this ASX materials stock
• Why 4DMedical, Develop Global, EOS, and Maas shares are racing higher today
• Why this dividend paying ASX All Ords share is tipped to outperform again in 2026
• Why this small cap ASX share could deliver a 40% return
• 5 things to watch on the ASX 200 on Wednesday

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Ipd Group. The Motley Fool Australia has positions in and has recommended Ipd Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The rise of artificial intelligence (AI) has served as an unprecedented bellwether for technology stocks over the last three years. In particular, semiconductor stocks including Nvidia, Taiwan Semiconductor Manufacturing, and Broadcom were all ushered into the trillion-dollar club thanks to the AI revolution. 

As investment in AI infrastructure continues to unfold, I think it’s likely that chip stocks will remain sound investment choices. But as 2026 approaches, I see a different tech titan taking center stage: Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG).

Let’s dig into how Alphabet has built an AI fortress poised to dominate the future. From there, I’ll explore the company’s valuation trends and make the case for why now is a great time to buy Alphabet stock hand over fist. 

It’s been a quiet three years for Alphabet…until now

The AI revolution kicked off almost exactly three years ago when OpenAI commercially launched ChatGPT. ChatGPT quickly captured the imaginations of people all over the world with its ability to answer virtually any question instantly.

The dramatic rise in popularity among large language models (LLMs) caused some on Wall Street to pose the idea that traditional search tools like Google were headed for doom. Think of the business stakes at hand here: Why would advertisers continue paying a premium on platforms like Google and YouTube when everyone’s attention was flocking to chatbots?

While Alphabet’s advertising business did show some signs of stalling, the company’s cash cow remained somewhat resilient. For a couple of years, revenue from Google and YouTube wasn’t as robust as it once was, but it also wasn’t plummeting at an alarming rate.

What many investors were overlooking, however, was Alphabet’s other ventures. At the beginning of the AI revolution, Google Cloud was operating at an annual revenue run rate of about $29 billion. Meanwhile, this segment of Alphabet’s business was unprofitable.

Fast forward to today, and Google Cloud is now on pace for more than $50 billion of annual sales while boasting positive operating income. What’s even more interesting is that Google Cloud has won major deals with both OpenAI and Anthropic — the two LLMs that were once seen as the ultimate existential threat to Google’s relevancy.

Besides the success of its cloud division, Alphabet has also successfully launched its own LLM — called Gemini. According to management, Gemini has over 650 million monthly active users (MAUs) while search queries are increasing threefold quarter over quarter.

Why 2026 could be epic for Gemini

For most of the AI revolution, I think the consensus view around Alphabet was one of uncertainty. While not everyone bought into the extinction of Google narrative, it’s fair to say that it took some time for Alphabet to prove its AI ambitions were bearing fruit.

One of the biggest catalysts the company has going into next year is an extension of Google Cloud through commercializing custom hardware. Specifically, Alphabet’s application-specific integrated circuits (ASICs), known as tensor processing units (TPUs), have seen some early traction with Apple and Anthropic.

While TPUs aren’t going to dethrone Nvidia’s GPU business anytime soon, I think Alphabet is on the cusp of unlocking a new wave of growth in the cloud infrastructure market that’s currently dominated by Amazon Web Services (AWS) and Microsoft Azure.

Alphabet stock could soar to new highs next year

As of this writing, Alphabet’s forward price to earnings (P/E) ratio is hovering around 28 — its highest level during the AI boom.

GOOGL PE Ratio (Forward) data by YCharts

Normally, I tend to stay away from momentum stocks. More times than not, by the time a company reaches a record high, it’s dicey to buy the premium and expect shares to move materially higher.

This is a rare instance where I think the opposite is true. Alphabet’s current price increase reflects two factors: An appreciation for the company’s current operating performance and a bullish outlook that Alphabet will keep up its strong performance.

Alphabet’s ecosystem — from search, cloud computing, consumer electronics, custom hardware, and more — is a major differentiator compared to its mega cap peers. The company has a unique flexibility stitched into its DNA — benefiting from AI across its various assets and subsidiaries during any market cycle. These dynamics position Alphabet as a particularly durable business for the long run.

As investments in AI infrastructure are expected to continue rising going into next year, I expect Alphabet to benefit from these tailwinds more so than any one singular chip designer or software developer.

With this in mind, I think Alphabet will continue to show signs of accelerating revenue and profit margin expansion across its entire business next year — which should lead to even more buying from shareholders. Against this backdrop, I see Alphabet as the best opportunity in the AI landscape as 2026 approaches. 

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post The best artificial intelligence (AI) stock to buy in 2026 (Hint: It’s not Nvidia) appeared first on The Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

More reading

• Which AI chip stock is the better buy for 2026: Nvidia or Alphabet?
• Should you buy this “Magnificent Seven” stock before 2026?
• Should you invest $1,000 in Alphabet right now?
• Better (almost) $4 trillion AI stock to buy now: Microsoft or Alphabet
• Why the best-performing “Magnificent Seven” stock of 2025 is still a buy for 2026

Adam Spatacco has positions in Alphabet, Amazon, Apple, Microsoft, and Nvidia. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Alphabet, Amazon, Apple, Microsoft, Nvidia, and Taiwan Semiconductor Manufacturing. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Broadcom and has recommended the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool Australia has recommended Alphabet, Amazon, Apple, Microsoft, and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.